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and 3 concluded to a non signiﬁcant effect. The qualitative evalua-
tion provided a median of 61% for the clinical data and of 50% for 
the FDG-PET data. SUV measurement and threshold for deﬁning 
high SUV were study dependent, 7 studies looked for a “best” cut-off 
(maximizing the logrank test statistic) however without adjusting the 
p value for multiplicity. Overall, the combined HR for the 12 reports 
was 2.29 (95% CI: 1.62-3.23) and test for heterogeneity was signiﬁcant 
(p=0.02); excluding the studies proposing a “best” cut-off, it decreased 
to 2.15 (95% CI: 1.16-3.97) but remained signiﬁcant (7 studies, n=475 
patients).
Conclusion: Our MA suggests that SUV max measured on primary 
tumor has a prognostic value in NSCLC; these results should be 
conﬁrmed in a MA based on individual patients data allowing to deﬁne 
more homogeneous groups in terms of SUV acquisition methods and 
timing, to perform a multivariate analysis adjusted for known and 
reproducible prognostic factors, to look more adequately at the deﬁni-
tion of high SUV and to take into account data from studies not fully 
dedicated to histologically proven lung cancer or from unpublished 
research works.
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Purpose: Approximately 20-40% of patients with surgically resected 
stage I non-small cell lung cancer will develop recurrent disease. There 
are no reliable markers that can identify those patients at highest risk of 
recurrence, who might beneﬁt from adjuvant therapy. Positron emission 
tomography (PET) with the glucose analogue 2-[18F] ﬂuoro-2-deoxy-
D-glucose (FDG) is used commonly in the staging of NSCLC. The 
primary tumor uptake of FDG assessed as the standardized uptake 
value (SUV) correlates with tumor doubling time. The purpose of this 
study was to determine whether the preoperative maximum tumor SUV 
(SUVmax) would predict eventual relapse in patients with resected 
stage I NSCLC.
Methods: We identiﬁed consecutive patients who had undergone cura-
tive surgical resection for stage I NSCLC (excluding pure bronchioloal-
veolar carcinoma) between 1999 and 2003 and who had preoperative 
FDG-PET imaging. Patients were divided into two equal cohorts based 
on SUVmax (above and below the median for the group). Recurrence 
rates for each cohort were estimated by the Kaplan-Meier method. 
Deaths without evidence of recurrence were treated as censoring 
events. Overall survival was calculated as a secondary endpoint. 
Results: Of 136 patients who met inclusion criteria, 77 (57%) had T1 
and 59 (43%) had T2 tumors. The median follow-up duration was 46 
months. The median SUVmax was 5.5. The estimated 5-year recur-
rence rates for patients with low SUVmax (< 5.5 ) and high SUVmax 
(≥ 5.5) were 13% and 36% respectively (p=0.002), with 5-year overall 
survival rates of 74% and 52% respectively (p=0.006). In stage IA pa-
tients, SUVmax was associated with a trend toward higher recurrence 
rates (12% vs 25%, p=0.14), and in stage IB patients SUVmax strongly 
correlated with recurrence (17% vs 46%, p=0.018). In a multivariate 
analysis for predictors of recurrence based on SUVmax, T classiﬁca-
tion, tumor size, age, and histology, only SUVmax was a statistically 
signiﬁcant predictor of recurrence (HR=2.9, p=0.008). 
Conclusions: High SUVmax (≥ 5.5) on preoperative FDG-PET is an 
independent predictor of relapse in resectable stage I NSCLC. Prospec-
tive trials of adjuvant chemotherapy in patients with stage I NSCLC 
and high SUVmax should be conducted.
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Background: Survival advantages have been demonstrated for 
advanced BAC patients with ipsilateral intrapulmonary metastasis at 
diagnosis, but it is not known whether these differences manifest in 
non-BAC NSCLC patients. 
Methods: We conducted a case-only analysis of U.S. Surveillance, Epi-
demiology, and End Results (SEER) data (1999-2003). Overall survival 
(OS) and lung cancer-speciﬁc survival (LCSS) univariate analyses were 
conducted using the Kaplan-Meier method. Multivariate survival analy-
ses were performed using Cox proportional hazards ratios. 
Results: 46,169 incident cases of histologically-conﬁrmed non-BAC 
NSCLC with complete TNM staging information available were identi-
ﬁed, including large cell carcinoma (LCC, n=1826, or 6.7%), squamous 
cell carcinoma (SqCC, n=5956, or 21.7%), undifferentiated carcinoma 
(n=8754, or 31.9%), and adenocarcinoma (n=10,899, or 39.7%). The 
majority of these NSCLC cases had advanced stage at presentation 
(stage I, n=11,106; stage II, n=1908; stage IIIa, n=5720; stage IIIb, 
n=7845; stage IV, n=19,590). Cases with stage IIIB non-BAC-NSCLC 
due to multiple lesions in the same lobe (n=633) had signiﬁcantly 
improved median OS (21 m) and LCSS (31m) compared to other stage 
IIIB NSCLC cases (n=7212; OS = 8 m, LCSS =9 m) (P<0.0001 for 
both OS and LCSS comparisons) (Figure 1). Among stage IV NSCLC 
cases, those with intrapulmonary metastasis (n=3010) had signiﬁcantly 
improved median OS (9m) and LCSS (11m) compared to those with 
distant metastasis (n=16,580; OS = 5m, LCSS = 6m) (P<0.0001 for 
both comparisons) (Figure 2). These survival differences persisted after 
